GDRX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

GD

Mkt Cap

$1.15B

Volume

783.80K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in RevenueGoodRx faces revenue stagnation with Q1 2026 sales declining 4.4% year-over-year to $194 million, though its Pharma Direct business showed encouraging 82% growth. Meanwhile, Hims & Hers Health demonstrates strong momentum with 59% year-over-year revenue growth in Q4 2025 and 13% subscriber growth, capitalizing on rising healthcare costs and limited access to primary care physicians.The Motley Fool · May 10, 2026

GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay MarketGoodRx Holdings shares rose 2.69% as the company expanded access to Novo Nordisk's Wegovy HD, a higher-dose GLP-1 treatment for self-pay patients priced at $399 per month. The expansion reflects growing demand for GLP-1 obesity treatments and GoodRx's efforts to simplify medication access. The company also recently expanded access to Eli Lilly's oral GLP-1 medication Foundayo and Zepbound.Benzinga · Apr 15, 2026

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.Amazon has entered the GLP-1 weight loss drug market by offering Novo Nordisk's Wegovy pill through its pharmacy service at competitive prices ($25-$149 per month). This move could significantly impact competitors like Hims & Hers, WW International, and GoodRx, as Amazon leverages its 200 million Prime members and e-commerce platform. While the pill form is expected to drive overall GLP-1 adoption, Amazon's scale and reach pose a competitive threat to specialized GLP-1 retailers.The Motley Fool · Feb 6, 2026

Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting CostNovo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive product launch, NVO stock remains down 35.61% over the past year and trades 8.4% below its 200-day moving average.Benzinga · Jan 5, 2026

Novo Nordisk Leans Into Affordability Amid Rising CompetitionNovo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.Benzinga · Nov 17, 2025

Telepharmacy Market Size to Reach US$ 21.89 Billion By 2032, Bridges Rural–Urban Healthcare Gap and Expands Digital Pharmacy Access | S&S InsiderThe telepharmacy market is projected to grow from $10.06 billion in 2024 to $21.89 billion by 2032, with a 10.23% annual growth rate. The market is driven by technological advancements, reducing healthcare disparities, and expanding digital pharmacy access, particularly in rural areas.GlobeNewswire Inc. · Sep 18, 2025

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock SkyrocketsGoodRx announced a collaboration with Novo Nordisk to offer Ozempic and Wegovy pens at $499/month for eligible self-paying patients, expanding medication access and meeting growing demand for GLP-1 medications.Benzinga · Aug 18, 2025

More Zero-cost Virtual Healthcare Appointments Available to Those Affected by Wildfires in Southern CaliforniaSesame, a healthcare marketplace, is offering no-cost virtual healthcare appointments to Los Angeles residents affected by wildfires, including primary care, prescription refills, and mental health medication management.GlobeNewswire Inc. · Jan 13, 2025

Why GoodRx Holdings Stock Was Sinking This WeekGoodRx's Q3 2023 earnings missed analyst estimates, with revenue and guidance falling short. The company's stock price dropped nearly 19% as a result, despite growth in key metrics like prescription transactions and monthly active consumers. Increased competition, particularly from Amazon's push into same-day pharmaceutical delivery, is seen as a challenge for GoodRx's future performance.The Motley Fool · Nov 8, 2024

RBC holds firm on GoodRx stock target with Outperform rating - Investing.comRBC Capital maintained its Outperform rating on GoodRx Holdings Inc. with a steady price target of $10.00. The upcoming quarterly report is anticipated to focus on the growth of Monthly Active Consumers, a key metric for the firm. RBC expects this growth to support GoodRx's guidance of mid-single-digit percentage revenue growth and an EBITDA margin surpassing 30%.Investing.com · Jul 17, 2024

GD

GDRXGoodRx Holdings, Inc. Class A Common Stock

GDRX

Pay with—

Available Balance0.00

Your PositionYou don't own any GDRX yet.

Related Tickers

Earnings